KRAS Mutation and NF-κB Activation Indicates Tolerance of Chemotherapy and Poor Prognosis in Colorectal Cancer

详细信息    查看全文

• 作者：Gen Lin (12)
  Xiong-wei Zheng (3)
  Chao Li (3)
  Qiang Chen (45) cqiang8@189.cn
  Yun-bin Ye (46) zjyunbin@189.cn
• 关键词：Colorectal carcinoma – NF ; κB – KRAS – Chemotherapy – Prognosis
• 刊名：Digestive Diseases and Sciences
• 出版年：2012
• 出版时间：September 2012
• 年：2012
• 卷：57
• 期：9
• 页码：2325-2333
• 全文大小：322.8 KB
• 参考文献：1. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327:293–297.
  2. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations in KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol. 2008;26:4217–4219.
  3. Lievre A, Bachet J-B, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treatment with cetuximab. J Clin Oncol. 2008;26:374–379.
  4. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell. 2008;132:344–362.
  5. Maeda S, Omata M. Inflammation and cancer: role of NF-kappaB activation. Cancer Sci. 2008;99:836–842.
  6. Clevers H. At the crossroads of inflammation and cancer. Cell. 2004;118:671–674.
  7. Sakamoto K, Maeda S. Targeting NF-kappaB for colorectal cancer. Expert Opin Ther Targets. 2010;14:593–601.
  8. Rakitina TV, Vasilevskaya IA, Dwyer PJ. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of NF κB signaling. Cancer Res. 2003;63:8600–8605.
  9. Camp RR, Li J, Minnich DJ, et al. Inducible NF kB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg. 2004;199:249–258.
  10. Uetsuka H, Haisa M, Kimura M, et al. Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res. 2003;289:27–35.
  11. Abdel-Latif MM, O’Riordan J, Windle HJ, et al. NF-kappaB activation in esophageal adenocarcinoma relationship to Barret’s metaplasia, survival and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239:491–500.
  12. Kojima M, Morisaki T, Sasaki N, et al. Increased NF-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res. 2004;24:675–681.
  13. Izzo JG, Malhotra U, Wu T–T, et al. Association of activated factor NF κB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006;24:748–754.
  14. Scartozzi M, Bearzi I, Pierantoni C, et al. NF-κB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol. 2007;25:3930–3935.
  15. Wong KK, Jacks T, Dranoff G. NF-kappaB fans the flames of lung carcinogenesis. Cancer Prev Res (Phila). 2010;3:403–405.
  16. Finco TS, Westwick JK, Norris JL, et al. Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem. 1997;272:24113–24116.
  17. Arsura M, Mercurio F, Oliver AL, et al. Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol Cell Biol. 2000;20:5381–5391.
  18. Mayo MW, Wang CY, Cogswell PC, et al. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science. 1997;278:1812–1815.
  19. Jo H, Zhang R, Zhang H, et al. NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene. 2000;19:841–849.
  20. Bassres DS, Ebbs A, Levantini E, et al. Requirement of the NF-kappaB subunit p65/RelA for KRAS-induced lung tumorigenesis. Cancer Res. 2010;70:3537–3546.
  21. Shen Y, Ye Y, Zheng X, Li C, Chen Q. KRAS mutations in the plasma of colorectal cancer patients. Lab Med. 2010;41:156–158.
  22. Lind DS, Hochwald SN, Malaty J, et al. NF-kappa B is upregulated in colorectal cancer. Surgery. 2001;130:363–369.
  23. Yu HG, Yu LL, Yang Y, et al. Increased expression of RelA/NF-kappa B protein correlates with colorectal tumorigenesis. Oncology. 2003;65:37–45.
  24. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108–112.
  25. Cadoret A, Bertrand F, Baron-Delage S, et al. Down-regulation of NF-kappaB activity and NF-kappaB p65 subunit expression by ras and polyoma middle T oncogenes in human colonic Caco-2 cells. Oncogene. 1997;14:1589–1600.
  26. Evertsson S, Sun XF. Protein expression of NF-kappaB in human colorectal adenocarcinoma. Int J Mol Med. 2002;10:547–550.
  27. Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15:699–731.
  28. Brandi G, Pantaleo MA, Biasco G, Paterini P. Activated NF-κB in colorectal cancer: predictive or prognostic factor? J Clin Oncol. 2008;26:1388–1389.
  29. Al Mulla F, MacKenzie EM. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol. 2001;195:549–556.
  30. Al Mulla F, Milner-White EJ, Going JJ, Birnie GD. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol. 1999;187:433–438.
  31. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304:1812–1820.
  32. Rohrer J, Wuertz BR, Ondrey F. Cigarette smoke condensate induces NF kappa-b activity and proangiogenic growth factors in aerodigestive cells. Laryngoscope. 2010;120:1609–1613.
  33. Preciado D, Kuo E, Ashktorab S, et al. Cigarette smoke activates NF-kappaB-mediated TNF-α release from mouse middle ear cells. Laryngoscope. 2010;120:2508–2515.
• 作者单位：1. Graduate School of Education, Fujian Medical University, Fuzhou, Fujian Province 350014, People’s Republic of China2. Department of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, Fujian Province 350014, People’s Republic of China3. Department of Pathology, Fujian Medical university, Fuzhou, Fujian Province 350014, People’s Republic of China4. Fujian Key Laboratory of Translational Cancer Medicine, Fuzhou, Fujian Province 350014, People’s Republic of China5. Department of Medical Oncology, Union Hospital of Fujian Medical University, Fuzhou, Fujian Province 350014, People’s Republic of China6. Laboratory of Immuno-Oncology, Fujian Provincial Cancer Hospital, Fujian Medical university, Fuzhou, Fujian Province 350014, People’s Republic of China
• ISSN：1573-2568

文摘

Background Evidence shows a strong relationship between KRAS mutations and the NF-κB signaling pathway. In colorectal cancer, however, the study of this subject has been very limited and results are inconsistent.